is tirzepatide covered by medicaid Under a regulation proposed last week the Centers for Medicare & Services (CMS), Medicare and Medicaid recipients with obesity could gain access to coverage for costly GLP-1 receptor agonists like Biden administration plans to expand

If youre tired of expensive spa treatments and want the convenience of professional-grade infrared therapy at home, an infrared sauna blanket might be the game-changer youve been looking for

Stick to your schedule

For health technology assessment (HTA) and payer teams, the access question will likely focus on the credibility of systolic blood pressure as the decision-relevant endpoint, the positioning of the drug after multi-drug background therapy, and the monitoring requirements for potassium and sodium

These data position survodutide as a leading glucagon/GLP-1 receptor dual agonist that could be a game-changer for people living with MASH and clinically significant fibrosis. The full trial results were also published in The New England Journal of Medicine

Some patients may experience persistent mild bloating that becomes their "new normal" on therapy